⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2829 | 0.78 | — | — | |
| SCHEMBL2338 | 0.75 | — | — | |
| SCHEMBL1023703 | 0.73 | — | — | |
| SCHEMBL3882820 | 0.73 | TRIM24 (0.40) | — | |
| SCHEMBL11473398 | 0.73 | TRIM24 (0.40) | — | |
| SCHEMBL5856925 | 0.73 | — | — | |
| SCHEMBL9415911 | 0.73 | TRIM24 (0.40) | — | |
| SCHEMBL2139113 | 0.70 | — | — | |
| SCHEMBL260392 | 0.70 | — | — | |
| SCHEMBL3876418 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1627 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4392424-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-07-03 | — | — | EP | claimed |
| US-20240173326-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-05-30 | — | — | US | claimed |
| WO-2024101336-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | 国立大学法人京都大学 | 2024-05-16 | — | — | WO | claimed |
| US-20240148732-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | SCHRÖDINGER, INC. | 2024-05-09 | — | — | US | claimed |
| US-20240140986-A1 | SYNTHETIC URSOLIC ACID DERIVATIVES AND METHODS OF USE THEREOF | REATA PHARMACEUTICALS, INC. | 2024-05-02 | — | — | US | claimed |
| US-20240108626-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A TYPE II PRMT INHIBITOR | IDEAYA BIOSCIENCES, INC. | 2024-04-04 | — | — | US | claimed |
| EP-4284804-A1 | TRICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISORDERS | Schrödinger, Inc. (US) | 2023-12-06 | — | — | EP | claimed |
| CN-117120442-A | Tricyclic compounds useful for treating cancer, autoimmune disorders, and inflammatory disorders | 薛定谔公司 | 2023-11-24 | — | — | CN | claimed |
| EP-4277916-A1 | SYNTHETIC URSOLIC ACID DERIVATIVES AND METHODS OF USE THEREOF | Reata Pharmaceuticals, Inc. (US) | 2023-11-22 | — | — | EP | claimed |
| CN-117015548-A | Synthetic ursolic acid derivatives and methods of use thereof | 里亚塔医药公司 | 2023-11-07 | — | — | CN | claimed |
| US-20050267105-A1 | Bicyclic heterocycles as HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-01 | — | — | US | claimed |
| US-20050113379-A1 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands | AVENTIS PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | claimed |
| WO-2005028480-A2 | 5-ARYL-PYRAZOLO[4,3-D]PYRIMIDINES, PYRIDINES, AND PYRAZINES AND RELATED COMPOUNDS | NEUROGEN CORPORATION (US) | 2005-03-31 | — | — | WO | claimed |
| WO-2005023806-A2 | HETEROARYL FUSED PYRIDINES, PYRAZINES AND PYRIMIDINES AS CRF1 RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-03-17 | — | — | WO | claimed |
| US-5789419-A | CARDIOVASCULAR AND BRONCHIAL DISORDERS | SS PHARMACEUTICAL CO., LTD. (JP) | 1998-08-04 | — | — | US | claimed |
| EP-0764639-A1 | 4-QUINOLINONE DERIVATIVE OR SALT THEREOF | SS PHARMACEUTICAL CO., LTD. (JP) | 1997-03-26 | — | — | EP | claimed |
| EP-0449191-B1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | BANYU PHARMA CO LTD (JP) | 1996-07-03 | — | — | EP | claimed |
| US-5438054-A | Antibacterial agent | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1995-08-01 | — | — | US | claimed |
| WO-1991014687-A1 | 2-(SUBSTITUTED PYRROLIDINYLTHIO)CARBAPENEM DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-10-03 | — | — | WO | claimed |
| EP-0449191-A1 | 2-(Substituted pyrrolidinylthio)carbapenem derivatives | Banyu Pharmaceutical Co., Ltd. (JP) | 1991-10-02 | — | — | EP | claimed |